Background: Studies showed that PM might be associated with various neurogenic diseases such as Alzheimer's Disease (AD). However, this topic had been little studied in Zhejiang province of China. METHODS: In 2018, we established a cohort of AD high-risk population with 1,742 elderly aged 60 and above. In 2020, the cohort was followed up, a total of 1,545 people participated the 2 surveys. Data collection included questionnaires and basic physical examinations. The average residential exposure to PM for each participant, that in a 5-years period prior to the first survey, was estimated using a satellite-based spatial statistical model. We determined the association between PM and AD prevalence by cox proportional hazards regression model. RESULTS: This study showed that an increase in the PM level was an important associated risk factor that contributed to AD. The average PM exposure levels among the study population ranged from 32.69 μg/m to 39.67 μg/m from 2013 to 2017, which were much higher than 5 μg/m that specified in the WHO air quality guidelines. There was an association between PM exposure and AD, and the correlations between PM and Mini-Mental State Examination, Montreal cognitive assessment scale scores were statistically significant. An increase in the PM level by 10 μg/m elevated the risk of AD among residents by 2%-5% (HR = 1.02 to 1.05, CI = 1.01-1.10). The subgroups of male, with old age, with low education levels, used to work as farmers or blue-collar workers before retirement, overweight and obese were associated with a higher effect of PM.
Conclusions: Reducing PM exposure might be a good way to prevent AD.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706836 | PMC |
http://dx.doi.org/10.1186/s12940-022-00937-w | DOI Listing |
Biomed Phys Eng Express
January 2025
Shandong University of Traditional Chinese Medicine, Qingdao Academy of Chinese Medical Sciences, Jinan, Shandong, 250355, CHINA.
Mild cognitive impairment (MCI) is a significant predictor of the early progression of Alzheimer's disease, and it can be used as an important indicator of disease progression. However, many existing methods focus mainly on the image itself when processing brain imaging data, ignoring other non-imaging data (e.g.
View Article and Find Full Text PDFACS Chem Neurosci
January 2025
Department of Bioengineering and Biotechnology, Birla Institute of Technology Mesra, Ranchi, Jharkhand 835215, India.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, extracellular amyloid-β (Aβ) plaque accumulation, and intracellular neurofibrillary tangles. Recent efforts to find effective therapies have increased interest in natural compounds with multifaceted effects on AD pathology. This study explores natural compounds for their potential to mitigate AD pathology using molecular docking, ADME screening, and assays, with ruscogenin─a steroidal sapogenin from emerging as a promising candidate.
View Article and Find Full Text PDFJ Neurosurg
January 2025
4Department of Neurosurgery, Korea University Anam Hospital, Seoul, Republic of Korea.
Objective: Focused ultrasound (FUS)-mediated blood-brain barrier (BBB) opening is safe and potentially beneficial in patients with Alzheimer's disease (AD) for the removal of amyloid-beta (Aβ) plaques. However, the optimal BBB opening intervals and number of treatment sessions for clinical improvement remain undefined. Therefore, the aim of this study was to evaluate the safety and benefits of repeated and more extensive BBB opening alone.
View Article and Find Full Text PDFOptom Vis Sci
January 2025
School of Optometry and Vision Science, UNSW Sydney, Sydney, New South Wales, Australia.
Significance: In an aging population, the number of people living with neurodegenerative disease is projected to increase. It is vital to develop reliable, noninvasive biomarkers to detect disease onset and monitor progression, and there is a growing body of research into the ocular surface as a potential source of such biomarkers.
Background: This article reviews the potential of in vivo corneal confocal microscopy and tear fluid analysis as tools for biomarker development.
Am J Ther
January 2025
James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, OH.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!